US Pharma MarketingAs general-purpose AI like ChatGPT and Gemini make its way into people's everyday lives today, domain-specific ones like AI in cancer are also advancing, with only funding and critical infrastructure standing in the way of clinical use, according to one of Hong Kong's leading researchers.
AI in cancer research waits for its funding moment
While cancer imaging AI is advancing, it still requires validation, infrastructure, and industry support for wider clinical use, says University of Hong Kong professor Kevin Tsia. As general-purpose AI like ChatGPT and Gemini make its way into people's everyday lives today, domain-specific ones like AI in cancer are also advancing, with only funding and critical infrastructure standing in the way of clinical use, according to one of Hong Kong's leading researchers. General-purpose AI fetched around $33.9 billion in investments in 2024, according to Stanford HAI's 2025 AI Index, while the AI in cancer market, which covers drug discovery, de novo…
Source: MobiHealthNews